Niki BioSolutions, Inc.
NIKI
$9.57
-$0.30-3.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 617.20K | 411.90K | 303.20K | 303.20K | 458.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 116.20K | -64.10K | -111.50K | -111.50K | 355.10K |
| Total Operating Expenses | 825.10K | 589.60K | 201.40K | 201.40K | 529.20K |
| Operating Income | -825.10K | -589.60K | -201.40K | -201.40K | -529.20K |
| Income Before Tax | -310.50K | -616.60K | -224.60K | -224.60K | -770.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -310.50K | -616.60K | -224.60K | -224.60K | -770.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 3.00K | 2.60K | 3.80K | 3.80K | -149.60K |
| Net Income | -307.50K | -614.00K | -220.90K | -220.90K | -919.90K |
| EBIT | -825.10K | -589.60K | -201.40K | -201.40K | -529.20K |
| EBITDA | -761.40K | -525.90K | -137.60K | -137.60K | -465.50K |
| EPS Basic | -0.38 | -0.86 | -0.31 | -0.31 | -1.64 |
| Normalized Basic EPS | -0.24 | -0.54 | -0.19 | -0.19 | -0.18 |
| EPS Diluted | -0.38 | -0.88 | -0.31 | -0.31 | -1.64 |
| Normalized Diluted EPS | -0.24 | -0.54 | -0.19 | -0.19 | -0.18 |
| Average Basic Shares Outstanding | 801.00K | 714.40K | 712.70K | 712.70K | 561.00K |
| Average Diluted Shares Outstanding | 801.00K | 714.40K | 712.70K | 712.70K | 561.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |